|
1
|
Seidel C, Dörner N, Osswald M, Wick A,
Platten M, Bendszus M and Wick W: Does age matter?-A MRI study on
peritumoral edema in newly diagnosed primary glioblastoma. BMC
Cancer. 11:1272011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schoenegger K, Oberndorfer S, Wuschitz B,
Struhal W, Hainfellner J, Prayer D, Heinzl H, Lahrmann H, Marosi C
and Grisold W: Peritumoral edema on MRI at initial diagnosis: An
independent prognostic factor for glioblastoma? Eur J Neurol.
16:874–878. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng L, Huang Z, Zhou W, Wu Q, Donnola S,
Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, et al: Glioblastoma
stem cells generate vascular pericytes to support vessel function
and tumor growth. Cell. 153:139–152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda Y, Myskiw C, Rommel A and Verma IM:
Mechanisms of neovascularization and resistance to anti-angiogenic
therapies in glioblastoma multiforme. J Mol Med (Berl). 91:439–448.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu S, Ahn D, Johnson G, Law M, Zagzag D
and Grossman RI: Diffusion-tensor MR imaging of intracranial
neoplasia and associated peritumoral edema: Introduction of the
tumor infiltration index. Radiology. 232:221–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin ZX: Glioma-related edema: New insight
into molecular mechanisms and their clinical implications. Chin J
Cancer. 32:49–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hartmann M, Jansen O, Egelhof T, Forsting
M, Albert FK and Sartor K: Effect of brain edema on the recurrence
pattern of malignant gliomas. Radiologe. 38:948–953. 1998.(In
German). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelhorn T, Savaskan NE, Schwarz MA,
Kreutzer J, Meyer EP, Hahnen E, Ganslandt O, Dörfler A, Nimsky C,
Buchfelder M and Eyüpoglu IY: Cellular characterization of the
peritumoral edema zone in malignant brain tumors. Cancer Sci.
100:1856–1862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou Y, Larsen PH, Hao C and Yong VW:
CXCR4 is a major chemokine receptor on glioma cells and mediates
their survival. J Biol Chem. 277:49481–49487. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bian XW, Yang SX, Chen JH, Ping YF, Zhou
XD, Wang QL, Jiang XF, Gong W, Xiao HL, Du LL, et al: Preferential
expression of chemokine receptor CXCR4 by highly malignant human
gliomas and its association with poor patient survival.
Neurosurgery. 61:570–579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ehtesham M, Winston JA, Kabos P and
Thompson RC: CXCR4 expression mediates glioma cell invasiveness.
Oncogene. 25:2801–2806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stevenson CB, Ehtesham M, McMillan KM,
Valadez JG, Edgeworth ML, Price RR, Abel TW, Mapara KY and Thompson
RC: CXCR4 expression is elevated in glioblastoma multiforme and
correlates with an increase in intensity and extent of peritumoral
T2-weighted magnetic resonance imaging signal abnormalities.
Neurosurgery. 63:560–570. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barbero S, Bonavia R, Bajetto A, Porcile
C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T and
Schettini G: Stromal cell-derived factor 1alpha stimulates human
glioblastoma cell growth through the activation of both
extracellular signal-regulated kinases 1/2 and Akt. Cancer Res.
63:1969–1974. 2003.PubMed/NCBI
|
|
14
|
Lin ZX: Patterns in the occurrence and
development of tumors. Chin Med J (Engl). 124:1097–1104.
2011.PubMed/NCBI
|
|
15
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zagzag D, Esencay M, Mendez O, Yee H,
Smirnova I, Huang Y, Chiriboga L, Lukyanov E, Liu M and Newcomb EW:
Hypoxia- and vascular endothelial growth factor-induced stromal
cell-derived factor-1alpha/CXCR4 expression in glioblastomas: One
plausible explanation of Scherer's structures. Am J Pathol.
173:545–560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu B, Chien EY, Mol CD, Fenalti G, Liu W,
Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, et al: Structures
of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide
antagonists. Science. 330:1066–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshie O, Imai T and Nomiyama H: Novel
lymphocyte-specific CC chemokines and their receptors. J Leukoc
Biol. 62:634–644. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Furusato B, Mohamed A, Uhlén M and Rhim
JS: CXCR4 and cancer. Pathol Int. 60:497–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hong X, Jiang F, Kalkanis SN, Zhang ZG,
Zhang XP, DeCarvalho AC, Katakowski M, Bobbitt K, Mikkelsen T and
Chopp M: SDF-1 and CXCR4 are up-regulated by VEGF and contribute to
glioma cell invasion. Cancer Lett. 236:39–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu DY, Tang CH, Yeh WL, Wong KL, Lin CP,
Chen YH, Lai CH, Chen YF, Leung YM and Fu WM: SDF-1alpha
up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and
NF-kappaB-dependent pathway in microglia. Eur J Pharmacol.
613:146–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kryczek I, Lange A, Mottram P, Alvarez X,
Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, et al: CXCL12
and vascular endothelial growth factor synergistically induce
neoangiogenesis in human ovarian cancers. Cancer Res. 65:465–472.
2005.PubMed/NCBI
|
|
24
|
Mirshahi F, Pourtau J, Li H, Muraine M,
Trochon V, Legrand E, Vannier J, Soria J, Vasse M and Soria C:
SDF-1 activity on microvascular endothelial cells: Consequences on
angiogenesis in in vitro and in vivo models. Thromb Res.
99:587–594. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guleng B, Tateishi K, Ohta M, Kanai F,
Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, et
al: Blockade of the stromal cell-derived factor-1/CXCR4 axis
attenuates in vivo tumor growth by inhibiting angiogenesis in a
vascular endothelial growth factor-independent manner. Cancer Res.
65:5864–5871. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tachibana K, Hirota S, Iizasa H, Yoshida
H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N,
Nishikawa S, et al: The chemokine receptor CXCR4 is essential for
vascularization of the gastrointestinal tract. Nature. 393:591–594.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lv S, Sun B, Zhong X, Dai C, Wang W, Ma X,
Song H, Shi R and Wang R: The clinical implications of chemokine
receptor CXCR4 in grade and prognosis of glioma patients: A
meta-analysis. Mol Neurobiol. 52:555–561. 2015. View Article : Google Scholar : PubMed/NCBI
|
